Loading clinical trials...
Loading clinical trials...
A Phase 1 Study to Evaluate the Effect of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Conditions
Interventions
Alisertib
Itraconazole
Locations
4
United States
St Louis, Missouri, United States
Oklahoma City, Oklahoma, United States
Germantown, Tennessee, United States
Dallas, Texas, United States
Start Date
October 22, 2014
Primary Completion Date
March 27, 2015
Completion Date
October 21, 2016
Last Updated
September 20, 2019
NCT07177937
NCT07387068
NCT07360314
NCT07403721
NCT07539285
NCT07524348
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions